CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Intellia Completes Enrollment in Phase 3 Nex-z Trial for Hereditary ATTR Amyloidosis With Polyneuropathy

By Public Technologies
  • Intellia Therapeutics completed enrollment in its Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary transthyretin amyloidosis with polyneuropathy.
  • The placebo-controlled study will evaluate efficacy and safety in approximately 60 patients; enrollment completion is not a clinical outcome.
  • The investigational, one-time gene-editing treatment targets liver production of transthyretin, aiming to halt or reverse disease progression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869049) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk